LOGIN  |  REGISTER
Astria Therapeutics

Latest Merger & Acquisition Life Science News

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

December 23
Last Trade: 1.65 0.10 6.45

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to result in approximately $175 million to support further development of IMG-007, including $75 million from an oversubscribed Private Placement that will close immediately following the merger The Financing includes...Read more


OraSure Technologies Acquires Sherlock Biosciences

December 19
Last Trade: 3.62 -0.02 -0.55

BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure’s innovation pipeline with the addition of Sherlock’s...Read more


Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

December 18
Last Trade: 0.45 0.03 6.72

Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi’s existing cash and Cara’s anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in...Read more


Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

December 17
Last Trade: 10.65 0.15 1.43

Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business BILLERICA, Mass. / Dec 17, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. (“EMISSION”). Quanterix expects the transaction will close in January...Read more


electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

December 17
Last Trade: 17.52 2.25 14.73

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered...Read more


Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics

December 17
Last Trade: 5.39 -0.57 -9.56

WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, is pleased to announce that it has entered into a Letter of Intent (“LOI”) with Immunova, LLC, (“Immunova”) a private Connecticut-based biotechnology company. Under the terms of the LOI,...Read more


HEALWELL AI to Acquire Orion Health, Creating a Global Market Leader in Healthcare Data Interoperability & Artificial Intelligence, and Launches $50 Million Bought Deal Financing

December 16
Last Trade: 2.10 0.10 5.00

HEALWELL AI has entered into an agreement to acquire 100% of the shares of Auckland, New Zealand based Orion Health Holdings Limited (“Orion Health”), a subscription license and services revenue business serving marquee public sector clients globally with data interoperability and healthcare navigation products and services. The two organisations are perfectly aligned on a combined mission to revolutionize healthcare through AI and...Read more


AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline

December 13
Last Trade: 178.39 -4.54 -2.48

Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoimmune diseases where significant unmet needs remain Acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics NORTH CHICAGO, Ill. and...Read more


Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share

December 12
Last Trade: 3.07 -0.02 -0.65

Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn., Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC) at a price of $3.10 per share in cash....Read more


TuHURA Biosciences Enters into Definitive Merger Agreement to Acquire Kineta

December 12
Last Trade: 0.39 -0.03 -6.14

Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURA's therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapy Proposed Transaction expected to close in Q1 2025 TAMPA, FL AND SEATTLE, WA / ACCESSWIRE / December 12, 2024 /...Read more


AbbVie Completes Acquisition of Aliada Therapeutics

December 11
Last Trade: 178.39 -4.54 -2.48

Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R&D capabilities NORTH CHICAGO, Ill., Dec. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of...Read more


Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

December 11
Last Trade: 17.83 -0.17 -0.94

VAUGHAN, Ontario / Dec 11, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to...Read more


Neuronetics and Greenbrook TMS Announce Closing of Transaction

December 10
Last Trade: 1.33 -0.06 -4.32

MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuronetics, the “Combined Company”) today announced that they have successfully completed the previously announced transaction whereby Neuronetics acquired all of the issued and outstanding common shares of Greenbrook (the “Greenbrook Shares”) by way of a...Read more


Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

December 9
Last Trade: 3.07 -0.02 -0.65

JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, today announced that they have amended and restated the merger agreement...Read more


Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction

December 6
Last Trade: 63.48 0.00 0.00

Transaction Expected to Close Towards the End of Calendar Year 2024 SOMERSET, N.J. & COPENHAGEN, Denmark / Dec 06, 2024 / Business Wire / Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional...Read more


HEALWELL AI Acquires Control of Mutuo Health Solutions to Build Next Generation of AI-Powered Physician Co-Pilots

HEALWELL has acquired a majority controlling interest in Mutuo Health Solutions, a Toronto-based medical artificial intelligence company focused on developing predictive clinical AI technology. Mutuo Health's AutoScribe platform is an advanced AI-powered ambient scribe solution that transcribes clinician-patient interactions into high-quality electronic medical records in real time using natural language processing and machine learning...Read more


XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

December 2
Last Trade: 26.62 -0.51 -1.88

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farmaceutici S.p.A; a Phase 3 study for pulmonary arterial hypertension is ongoing and is expected to read out in the fourth quarter of 20251 XOMA Royalty has the potential to net up to $25...Read more


GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

GE HealthCare to acquire 50% stake from Sumitomo Chemical to assume full ownership of NMP, subject to regulatory approvals As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, will enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease Acquisition positions NMP to become partner of choice for global innovators looking to bring novel...Read more


Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

November 26
Last Trade: 34.91 0.39 1.13

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies Roche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US $1.0 billion Stockholders would also receive a...Read more


Poseida Therapeutics Announces Agreement to be Acquired by Roche Holdings

November 26
Last Trade: 9.48 0.03 0.32

Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's...Read more


Boston Scientific Announces Agreement to Acquire Intera Oncology

November 25
Last Trade: 89.86 0.91 1.02

Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Intera Oncology® Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine – a chemotherapy...Read more


Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discovery Recursion will host an update call today, November 20, 2024 at 7:30...Read more


Boston Scientific Closes Acquisition of Axonics

November 15
Last Trade: 89.86 0.91 1.02

MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with...Read more


Halozyme Therapeutics Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

November 14
Last Trade: 47.14 0.18 0.38

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.00...Read more


BioNTech to Acquire Biotheus to Boost Oncology Strategy

November 13
Last Trade: 113.51 0.43 0.38

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumors With the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific...Read more


Recursion and Exscientia Shareholders Approve the Proposed Combination

Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia.  The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update...Read more


Pulmatrix and Cullgen Announce Proposed Merger

November 13
Last Trade: 5.79 -0.21 -3.50

Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain Combined company expected to have approximately $65 million of cash and cash equivalents at close to provide funding through multiple clinical milestones and expected runway through...Read more


Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

November 13
Last Trade: 0.62 -0.01 -1.59

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform and therapeutic products for unmet medical needs in oncology and autoimmune diseases and (ii) Entero’s gastrointestinal product pipeline for treating unmet metabolic and rare genetic diseases; The NIC platform technology is invented by and...Read more


Kane Biotech Announces Agreement to Acquire FB Dermatology

November 12
Last Trade: 0.10 -0.005 -5.00

WINNIPEG, Manitoba, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that it has entered into a binding term sheet (the “Term Sheet”) setting out the key terms and conditions relating to the acquisition of all of the issued and outstanding shares (the “Purchased Shares”) of FB Dermatology S.R.L. (“FB Dermatology”), incorporated under the laws of Italy. FB...Read more


Cardinal Health announces two strategic additions to its portfolio

November 11
Last Trade: 118.35 0.07 0.06

Acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to accelerate Cardinal Health's multi-specialty growth strategy Acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, to accelerate Cardinal Health's at-Home Solutions growth strategy Company announces plan to hold Investor Day in June...Read more


Astrana Health Announces Definitive Agreement to Acquire Certain Businesses and Assets of Prospect Health System

November 8
Last Trade: 33.47 -0.23 -0.68

ALHAMBRA, Calif., Nov. 8, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it and its affiliated professional entities have entered into a definitive agreement to acquire...Read more


AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

November 8
Last Trade: 0.45 0.05 11.39

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases Invented by VEGF pioneer Dr. Napoleone Ferrara, TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept, and could...Read more


Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Merger

November 8
Last Trade: 0.95 -0.02 -2.06

BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the...Read more


Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction

November 6
Last Trade: 12.27 -0.03 -0.24

TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”)...Read more


Boston Scientific Announces Agreement to Acquire Cortex

November 4
Last Trade: 89.86 0.91 1.02

Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution...Read more


WELL Health Technologies to Acquire Canadian Clinical Assets of Jack Nathan Health and Begin Operating Clinics in Wal-Mart Stores to Grow Healthcare Clinic Network Across Canada

November 4
Last Trade: 7.21 0.11 1.55

WELL to acquire Canadian clinical assets from Jack Nathan Medical Corp. including a network of 16 owned and operated clinics, which generated revenue of over $10 million in the past 12 months. The portfolio of owned and operated clinics is expected to operate profitably on an adjusted EBITDA basis in 2025, following immediate synergies with WELL's shared services program and application of WELL's clinic transformation program. WELL...Read more


Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

November 4
Last Trade: 4.40 0.00 0.00

GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has signed a non-binding letter of intent (LOI) with Renexxion, Inc. (Renexxion), a privately-held U.S.-based clinical-stage biotechnology company...Read more


NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

November 4
Last Trade: 1.98 0.03 1.54

ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA") ("Kadimastem"), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announced today that they have entered into a...Read more


Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement

October 31
Last Trade: 2.56 0.03 1.19

Merger to create a company focused on advancing Jade Biosciences’ portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025 Approximately $300 million raised to date, including anticipated proceeds from an...Read more


VitalHub Announces Acquisition of Strata Health

October 30
Last Trade: 11.00 0.00 0.00

TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Strata Health Solutions Inc. (“Strata Health”), a leading provider of patient flow solutions internationally. Based in Canada, Strata Health designs, builds, and deploys software that improves access and navigation to care. Strata Health has over 80 health system...Read more


NeueHealth Acquires Full Ownership of Centrum Health

October 30
Last Trade: 4.35 0.53 13.87

DORAL, Fla. / Oct 30, 2024 / Business Wire / NeueHealth, Inc. (“NeueHealth” or the “Company”) (NYSE: NEUE), the value-driven healthcare company, today announced that Centrum Health, one of the Company’s value-driven clinic brands, became a wholly owned subsidiary through the Company’s acquisition of the remaining 25% equity interest of the business that it did not already own. This action simplifies NeueHealth’s corporate structure,...Read more


GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

October 29
Last Trade: 0.22 -0.02 -7.65

Following closing, the combined company will advance Crescent’s portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent’s lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26 Crescent pipeline also includes two novel...Read more


AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline

October 28
Last Trade: 178.39 -4.54 -2.48

Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscience NORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today...Read more


Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

October 28
Last Trade: 14.70 0.12 0.82

The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. JERSEY CITY, N.J. / Oct 28, 2024 / Business Wire / Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company...Read more


Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

October 24
Last Trade: 0.62 0.0033 0.54

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate Data from ImmPACT’s multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3rd line CAR-naïve setting to be presented at a major medical conference later this year; initiation of a pivotal trial for IMPT-314 expected in 2025 Lyell has prioritized its pipeline to...Read more


Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)

October 23
Last Trade: 4.34 0.00 0.00

AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that the Company has entered into a definitive merger agreement, dated October 22, 2024 (the “Merger Agreement”) whereby Double Point Ventures LLC (“DPV”) will acquire 100% of Lumos Pharma’s outstanding shares of common...Read more


Ocuphire Pharma Announces Acquisition of Opus Genetics

October 22
Last Trade: 1.33 0.00 0.00

Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with...Read more


Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

October 16
Last Trade: 2.28 -0.05 -2.15

FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. (“Sequence”). “Rebound adds to our portfolio...Read more


Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women’s Health

October 14
Last Trade: 72.50 0.85 1.19

MARLBOROUGH, Mass. / Oct 14, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a global champion of women’s health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health for approximately $350 million, subject to working capital and other customary closing...Read more


Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

October 14
Last Trade: 60.00 0.00 0.00

The proposed acquisition represents a significant step forward in Lundbeck’s Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck’s capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster...Read more


Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

October 14
Last Trade: 4.68 -0.10 -2.09

Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or Stockholders WASHINGTON, Oct. 14, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it received a second unsolicited, non-binding proposal from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash. Cycle Group's second proposal was received...Read more


U.S. Physical Therapy Announces Acquisition of 50-Clinic Physical Therapy Management Services Organization

October 7
Last Trade: 89.84 -1.47 -1.61

HOUSTON / Oct 07, 2024 / Business Wire / U.S. Physical Therapy, Inc. ("USPH") (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that it has signed an agreement to purchase a 50% equity interest in a management services organization (the “Company”) that provides management and administrative services to 50 physical therapy clinics. The Company...Read more


Virios Therapeutics and Wex Pharmaceuticals Announce Business Combination to Form Dogwood Therapeutics

October 7
Last Trade: 0.16 0.00 0.00

Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development into 4Q25 Expanded pipeline includes a potential first-in-class non-opioid, NaV1.7 inhibition pain treatment, Halneuron®, currently in Phase 2b development for chemotherapy-induced neuropathic pain, with an expected interim readout...Read more


Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery

October 2
Last Trade: 57.39 0.39 0.68

Combining Dynamic Biosensors’ Innovative Technologies with Bruker’s High-Performance SPR Portfolio to Establish a Leading Biosensors Business MUNICH / Oct 02, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker’s biophysical...Read more


Kovo HealthTech Announces Acquisition of Right to Acquire Assets of AccelVue

September 30
Last Trade: 0.06 0.00 0.00

Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - Kovo HealthTech Corporation (TSXV: KOVO) ("Kovo" or the "Company") is pleased to announce that it has entered into an asset purchase agreement dated September 30, 2024 (the "Asset Purchase Agreement") with HEAL USA, Inc. ("HEAL USA") pursuant to which the Company will acquire from HEAL USA the exclusive right to purchase certain contractual assets of Coredynamex, LLC,...Read more


Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

September 30
Last Trade: 2.09 0.02 0.97

Business combination to form a best-in-class, transformative oral biologics company Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth Merger anticipated to close in 1Q25 BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in...Read more


Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market

September 24
Last Trade: 0.90 0.10 12.12

Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women The PrePsia test can predict preeclampsia risk as early as in the 12th week of pregnancy, allowing for early interventions to prevent serious health issues for mothers and their babies PrepSia will be commercialized in the U.S. market in 2025...Read more


Stryker completes acquisition of NICO Corporation, expanding minimally invasive solutions for brain tumor removal and stroke care

September 20
Last Trade: 366.49 1.89 0.52

PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. This acquisition further strengthens Stryker's commitment to neurotechnology through tumor and stroke...Read more


Agilent Technologies Completes Acquisition of BIOVECTRA

September 20
Last Trade: 134.60 0.93 0.70

Pharmaceutical customers will benefit from a broader set of specialized CDMO capabilities SANTA CLARA, Calif. / Sep 20, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted...Read more


Cardinal Health to acquire Integrated Oncology Network, a physician-led independent community oncology network

September 20
Last Trade: 118.35 0.07 0.06

Transaction demonstrates Cardinal Health's continued strategic investment in specialty and oncology, underscores commitment to independent community healthcare providers  Accelerates the development of Navista oncology practice alliance, adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 states DUBLIN, Ohio, Sept. 20, 2024 /PRNewswire/ --...Read more


Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital

September 19
Last Trade: 19.26 -0.29 -1.48

SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received an unsolicited non-binding proposal from Concentra Biosciences, LLC (“Concentra”) to acquire all of the Company’s outstanding shares of common stock for $12.00 per share in...Read more


Psyence Biomedical Enters into Agreement to Acquire Stake in PsyLabs

September 19
Last Trade: 0.02 0.00 0.00

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has entered into a conditional share sale agreement with Psyence Group (CSE: PSYG) (as seller) for the acquisition of an 11.13% stake in privately-held PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical...Read more


Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

September 18
Last Trade: 11.97 0.40 3.46

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon’s international dermatology capabilities to the U.S. BASEL, Switzerland and LONDON and NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the...Read more


Stryker completes acquisition of care.ai

September 17
Last Trade: 366.49 1.89 0.52

Portage, Michigan, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), announced that it has completed the previously announced acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. “We welcome the care.ai team to Stryker and look forward to working together to accelerate our digital vision to provide customers with...Read more


ANI Pharmaceuticals Completes Acquisition of Alimera Sciences

September 16
Last Trade: 54.21 0.86 1.61

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology Anticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive...Read more


Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

September 9
Last Trade: 0.19 0.0009 0.48

MOUNTAIN VIEW, Calif. & SAN DIEGO / Sep 09, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer, Evofem Biosciences, Inc. (OTCQB: EVFM) (“Evofem”) today announced they have entered into the Second Amendment to the Amended and Restated Agreement and Plan of Merger (the “Second Amendment”), under which Aditxt intends...Read more


Collegium Pharmaceutical Completes Acquisition of Ironshore Therapeutics

September 4
Last Trade: 29.15 -0.55 -1.85

Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD)  Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition  2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million  STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified...Read more


Becton Dickinson Completes Acquisition of Critical Care from Edwards Lifesciences

September 3
Last Trade: 226.44 -1.24 -0.54

Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision tools Combination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilities Business renamed as BD Advanced Patient Monitoring, will be based in Irvine,...Read more


Semnur Pharmaceuticals, a Wholly Owned Subsidiary of Scilex, and Denali Capital Acquisition Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value

September 3
Last Trade: 0.46 0.0095 2.12

Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”) announce the signing of an agreement and plan of merger for a proposed business combination (the “Business Combination Agreement”), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital...Read more


Semnur Pharmaceuticals, a Wholly Owned Subsidiary of Scilex, and Denali Capital Acquisition Announce Signing of a Merger Agreement for a proposed Business Combination

September 3
Last Trade: 0.46 0.0095 2.12

Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”) announce the signing of an agreement and plan of merger for a proposed business combination (the “Business Combination Agreement”), which provides for a pre-transaction equity value of Semnur of $2.5 billion.  The Board of Scilex, Semnur, and Denali...Read more


ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

August 29
Last Trade: 2.40 0.00 0.00

WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced completion of the merger with Oruka Therapeutics, Inc. (“Oruka”) following ARCA’s successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the “combined company.” As previously announced, the...Read more


Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation

August 26
Last Trade: 152.94 -0.16 -0.10

SECAUCUS, N.J. and TORONTO, Aug. 26, 2024 /CNW/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at approximately CAN $1.35 billion (approximately USD $1 billion), including net debt, has received all necessary approvals and is now closed. "This acquisition brings together two industry...Read more


Stryker announces definitive agreement to acquire Vertos Medical, expanding interventional pain management solutions

August 22
Last Trade: 366.49 1.89 0.52

Portage, Michigan, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis. Lumbar spinal stenosis affects millions of people globally and is a leading cause of pain and disability. Patients...Read more


Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

August 22
Last Trade: 0.60 -0.03 -4.44

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. & GAINESVILLE, Fla. / Aug 22, 2024 / Business Wire / Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they...Read more


Johnson & Johnson to Acquire V-Wave

August 20
Last Trade: 145.27 0.80 0.55

V-Wave’s Novel and Minimally Invasive Interatrial Shunt is Designed to Treat Heart Failure and Addresses Significant Treatment Gap Device Further Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular NEW BRUNSWICK, N.J. / Aug 20, 2024 / Business Wire / Johnson & Johnson1 (NYSE: JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on...Read more


Prenetics Global Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry

August 19
Last Trade: 5.66 0.17 3.10

Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics’ New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences...Read more


Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

August 19
Last Trade: 3.24 -0.14 -4.14

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by Titan’s board of directors (the “Board”). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other...Read more


Eli Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

August 16
Last Trade: 796.28 28.52 3.71

Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical...Read more


Stryker announces definitive agreement to acquire care.ai, a leading virtual care and ambient intelligence solutions platform

August 12
Last Trade: 366.49 1.89 0.52

Portage, Michigan, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. The acquisition will strengthen Stryker’s growing healthcare IT offering and wirelessly connected medical device...Read more


Crown Laboratories and Revance Therapeutics Announce Entry Into Merger Agreement

August 12
Last Trade: 3.07 -0.02 -0.65

Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company's flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizard® (sunscreen), and StriVectin® (anti-aging) Opportunity for global commercialization capabilities with coverage...Read more


Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge

August 12
Last Trade: 1.33 -0.06 -4.32

MALVERN, Pa. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”) today announced that they have entered into a definitive arrangement agreement (the “Definitive Agreement”) in which Neuronetics will acquire all of the outstanding common shares of Greenbrook in an all-stock transaction. “This transaction brings together two of the leaders...Read more


Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to...Read more


PetIQ Enters into Definitive Agreement to be Acquired by Bansk Group

August 7
Last Trade: 30.98 0.00 0.00

EAGLE, Idaho, and NEW YORK, New York, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, and Bansk Group (“Bansk”), a consumer-focused private investment firm dedicated to building distinctive consumer brands, today announced that PetIQ entered into a definitive agreement (the “Agreement”) pursuant to which Bansk Group will acquire all of the...Read more


Pharmacosmos Group to Acquire G1 Therapeutics

August 7
Last Trade: 7.15 0.00 0.00

Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1’s COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent  Pharmacosmos’ Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of COSELA for Patients with ES-SCLC  Transaction Expands and Strengthens Pharmacosmos’ Global Commercial...Read more


AbbVie Completes Acquisition of Cerevel Therapeutics

August 1
Last Trade: 178.39 -4.54 -2.48

Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade AbbVie reaffirms...Read more


CooperCompanies Acquires obp Surgical, Expanding CooperSurgical’s Portfolio of Leading Medical Devices

August 1
Last Trade: 92.52 -0.92 -0.98

SAN RAMON, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) --  CooperCompanies (Nasdaq: COO), today announced that CooperSurgical has acquired obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with an integrated multi-LED light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source, for approximately $100...Read more


R1 RCM to be Acquired by TowerBrook and CD&R for $8.9 Billion

August 1
Last Trade: 14.31 0.00 0.00

MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice (“CD&R”), in an all-cash...Read more


Pennant Completes Acquisition of Signature Healthcare at Home’s Washington and Idaho Assets

August 1
Last Trade: 26.83 -0.55 -2.01

EAGLE, Idaho, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it has completed its purchase of the Washington and Idaho assets of Signature Healthcare at Home. Pennant previously announced its agreement to purchase the Signature assets, with the planned closing of Signature’s Washington...Read more


Stryker completes acquisition of MOLLI Surgical

July 31
Last Trade: 366.49 1.89 0.52

SAN JOSE, California, USA, July 31, 2024 /CNW/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast conserving surgery. MOLLI's portfolio further strengthens Stryker's commitment to advancing surgical solutions in breast cancer...Read more


VitalHub to Acquire MedCurrent

July 30
Last Trade: 11.00 0.00 0.00

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has signed a definitive agreement (the “Definitive Agreement”) to acquire MedCurrent Corporation and its subsidiaries (“MedCurrent”), by way of a court-approved plan of arrangement under the provisions of the Business Corporations Act (Ontario) (the “Transaction”). MedCurrent is a...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB